BCABHealthcare · BiotechnologyBCAB Stock Forecast: BioAtla, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 21 Aug 2026 — in the lower half.
BCAB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores BioAtla, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BCAB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BCAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2025 | JMP Securities | Downgrade | Market Perform | — |
| 13 Aug 2025 | JMP Securities | Downgrade | Market Perform | — |
| 31 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 Nov 2024 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 23 May 2024 | JMP Securities | Maintains | Market Outperform | — |
| 15 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 27 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Sept 2023 | JP Morgan | Maintains | Overweight | — |
| 2 Aug 2023 | EF Hutton | Reiterates | Buy | — |
| 2 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Aug 2023 | JMP Securities | Reiterates | Market Outperform | — |
| 2 Aug 2023 | JP Morgan | Maintains | Overweight | — |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2023 | JMP Securities | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCAB appears on the weeks it earns a place.
BCAB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
BioAtla, Inc. (BCAB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- 0.6×
- Price / book
- −0.1×
- EV / EBITDA
- −0.3×
Cheaper than 77% of US stocks
Cheaper than 79% of US stocks
Cheaper than 93% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 3.5%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 51% of US stocks
Higher than 30% of US stocks
- Return on equity
- 164.7%
- Return on assets
- −107.6%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BCAB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioAtla, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BCAB stock
Is BCAB stock a buy right now?
Of the 1 analysts covering BioAtla, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioAtla, Inc. 26 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BCAB?
As at 21 Aug 2026, BioAtla, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the BCAB stock forecast for 2030?
No analyst covering BioAtla, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCAB are extrapolating price history, which says nothing about the business.
How has BCAB stock performed over the past year?
BioAtla, Inc. returned -82.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does BioAtla, Inc. do?
BioAtla, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of Conditionally Active Biologics (CAB) antibody therapeutics designed for solid tumors.
About BioAtla, Inc.
BioAtla, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, specializing in the development of Conditionally Active Biologics (CAB) antibody therapeutics designed for solid tumors. The CAB platform enables antibodies to activate selectively in the tumor microenvironment, enhancing safety and efficacy by minimizing activity in healthy tissues while targeting cancer-specific conditions. Key programs include ozuriftamab vedotin (Oz-V), a ROR2-targeting antibody-drug conjugate advancing in trials for HPV-positive oropharyngeal squamous cell carcinoma and head and neck cancers; mecbotamab vedotin (Mec-V), an AXL-targeting ADC evaluated in treatment-refractory soft tissue sarcomas and non-small cell lung cancer; and BA3182, a bispecific T-cell engager targeting EpCAM and CD3 for metastatic adenocarcinomas. BioAtla, Inc. focuses on oncology, leveraging proprietary technologies like Comprehensive Integrated Antibody Optimization (CIAO) to create next-generation biologics with improved therapeutic indices for challenging solid tumors.
CEO Dr. Jay M. Short Ph.D. · 41 employees · United States · https://www.bioatla.com